Immix Biopharma (IMMX) News Today $2.65 -0.06 (-2.21%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.64 -0.02 (-0.57%) As of 07/11/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication ExpansionJuly 11 at 9:36 AM | globenewswire.comImmix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% - Here's WhyJuly 9, 2025 | marketbeat.comImmix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - MorningstarJuly 8, 2025 | morningstar.comMImmix Biopharma, Inc.: Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL AmyloidosisJuly 8, 2025 | finanznachrichten.deImmix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL AmyloidosisJuly 7, 2025 | globenewswire.comImmix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street ZenJune 27, 2025 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 35.6% in MayJune 17, 2025 | marketbeat.comImmix Biopharma Attends FDA CEO Forum in Washington DCJune 6, 2025 | globenewswire.comH.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 TrialJune 6, 2025 | msn.comHC Wainwright Predicts Stronger Earnings for Immix BiopharmaJune 6, 2025 | marketbeat.comBrokers Issue Forecasts for Immix Biopharma Q1 EarningsJune 5, 2025 | marketbeat.comImmix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025June 5, 2025 | nasdaq.comImmix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis TrialJune 4, 2025 | msn.comImmix Biopharma (NASDAQ:IMMX) Receives "Buy" Rating from HC WainwrightJune 4, 2025 | marketbeat.comImmix Biopharma Enters At The Market Offering AgreementJune 3, 2025 | tipranks.comImmix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL AmyloidosisJune 3, 2025 | globenewswire.comImmix Biopharma Inc.May 27, 2025 | wsj.comImmix Biopharma (NASDAQ:IMMX) Trading Up 15.3% - Should You Buy?May 25, 2025 | marketbeat.comImmix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL AmyloidosisMay 24, 2025 | nasdaq.comImmix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2May 23, 2025 | globenewswire.comImmix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL AmyloidosisMay 22, 2025 | globenewswire.comImmix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL AmyloidosisMay 21, 2025 | globenewswire.comWe're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn RateMay 19, 2025 | finance.yahoo.comImmix Biopharma (IMMX) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 44.8% in AprilMay 1, 2025 | marketbeat.comImmix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025April 23, 2025 | globenewswire.comImmix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPSMarch 27, 2025 | marketbeat.comImmix Biopharma (IMMX) Projected to Post Quarterly Earnings on ThursdayMarch 20, 2025 | marketbeat.comImmix Biopharma stock holds $7 target, Buy rating at H.C. WainwrightFebruary 11, 2025 | msn.comImmix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL AmyloidosisFebruary 11, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Immix Biopharma (NASDAQ:IMMX)February 10, 2025 | marketbeat.comBuy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201February 10, 2025 | tipranks.comImmix Biopharma, Inc. Receives FDA RMAT Designation for CAR-T Therapy NXC-201 in Relapsed/Refractory AL AmyloidosisFebruary 10, 2025 | quiverquant.comQImmix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL AmyloidosisFebruary 10, 2025 | globenewswire.comSeveral Insiders Invested In Immix Biopharma Flagging Positive NewsFebruary 5, 2025 | finance.yahoo.comShort Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Declines By 11.0%January 19, 2025 | marketbeat.comFY2024 EPS Forecast for Immix Biopharma Decreased by AnalystJanuary 9, 2025 | marketbeat.comImmix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201January 8, 2025 | markets.businessinsider.comImmix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-TJanuary 7, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Acumen Pharmaceuticals (ABOS) and Immix Biopharma, Inc. (IMMX)January 6, 2025 | markets.businessinsider.comImmix Biopharma (NASDAQ:IMMX) Given "Buy" Rating at HC WainwrightJanuary 6, 2025 | marketbeat.comImmix Biopharma Reports Positive Early Results From NEXICART-2 Trial Of NXC-201 In AL AmyloidosisDecember 19, 2024 | markets.businessinsider.comImmix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) AmyloidosisDecember 19, 2024 | globenewswire.comImmix Biopharma, Inc.: Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL AmyloidosisDecember 18, 2024 | finanznachrichten.deImmix Biopharma reports promising CAR-T therapy resultsDecember 18, 2024 | uk.investing.comImmix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 17.5% in NovemberDecember 16, 2024 | marketbeat.comJournal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL AmyloidosisDecember 16, 2024 | globenewswire.comImmix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024December 10, 2024 | globenewswire.comWill Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?December 10, 2024 | uk.finance.yahoo.comImmix Biopharma to Host Conference Call for Investors, Analysts and Members of the MediaDecember 9, 2024 | globenewswire.com Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMX Media Mentions By Week IMMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMX News Sentiment▼0.591.01▲Average Medical News Sentiment IMMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMX Articles This Week▼61▲IMMX Articles Average Week Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Abeona Therapeutics News Today Inhibrx Biosciences News Today ADC Therapeutics News Today Candel Therapeutics News Today Sagimet Biosciences News Today Neurogene News Today Aardvark Therapeutics News Today Foghorn Therapeutics News Today Palvella Therapeutics News Today Zhengye Biotechnology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMX) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
